Eli Lilly and Co. (NYSE:LLY) reported better-than-expected third-quarter earnings on Thursday and boosted its annual forecast, sending the stock higher.
The U.S. weight loss drug giant reported quarterly revenue of $17.60 billion, up 54% year over year, beating the consensus of $16.02 billion. This growth was driven by a 62% increase in volume, partially offset by a 10% decrease due to lower realized prices.
